Anthropic faces intense competitive pressure and huge fixed costs. Can Claude build itself fast enough to succeed?
RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results